Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05754333 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
A Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
- 6
- Study locations
NCT05754333: Completed Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, sponsored by Astellas Pharma Global Development.
NCT05754333 is a Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 107 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05754333, a Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
- 6
- Study locations
Study Summary
The ureter was the tube that carries urine from the kidneys to the bladder. It was difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious. This study was about a potential new medical dye, called ASP5354. This dye was injected into the person at the start of surgery and was detected in the ureter. This was done by an imaging machine which had an option called near infrared fluorescence, or NIR-F. Together they showed live images of specific parts of the body. In this study, ASP5354 was used with an imaging machine with a NIR-F option to show live images of the ureter during surgery. People with kidneys that work properly and those with kidney problems could take part. The main aim of the study was to find out how clearly the ureter could be seen with ASP5354 during surgery in adults whose kidneys work properly or who have mild kidney problems. To do this, the surgeons injected ASP5354 into the person having surgery. Then, the surgeons compared images of the ureter with an imaging machine using normal white light and with the NIR-F option. Imaging using normal white light was the standard way surgeons see the ureter during surgery. People 12 years or older who were going to have certain abdominal surgeries could take part. Everyone taking part received ASP5354 during surgery, but how the imaging was done depended on which group they are in. Before surgery, the adults taking part whose kidneys work properly or who have mild kidney problems were assigned into 1 of 2 groups by chance alone. Images of the ureter were checked in 1 group using normal white light and the other group using normal white light and NIR-F. People 18 years and older with more severe kidney problems and all people under 18 years old were not be assigned to 1 of 2 groups: all images of the ureter were checked using normal white light and NIR-F. At the start of surgery, the surgeon injected ASP5354 into the per
Primary Outcome
Ureter conspicuity was scored individually for each illumination mode using a 5-Point Likert Scale, ranging from 1 to 5 where 1= none (not self-evident), 2= poor (somewhat self-evident), 3= sufficient (sufficiently self-evident), 4= good (clearly self-evident), 5= excellent (extremely self-evident). All participants had conspicuity scores from one ureter.
Conditions Studied
Interventions
- DRUG pudexacianinium chloride
Study Locations (6)
Florida
- AdventHealth Orlando - Orlando
- Advent Health Tampa - Tampa
- Cleveland Clinic Florida - Weston
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2023-08-02 |
| Est. Completion | 2025-01-16 |
| Phase | Phase 3 |
What the finished NCT05754333 record still lists
NCT05754333 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Intraoperative Ureter Visualization appearing as the primary indexed condition, and to 1 intervention - of which pudexacianinium chloride is the first listed.
NCT05754333 lists 6 locations in 4 states (Florida, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT05754333 about?
NCT05754333 is a clinical study titled "A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery". The ureter was the tube that carries urine from the kidneys to the bladder. It was difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious. This study was about a potential new medical dye, called ASP5354. This ...
What is the current status of trial NCT05754333?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2023-08-02. Estimated completion is 2025-01-16.
What conditions does trial NCT05754333 study?
This clinical trial studies the following conditions: Intraoperative Ureter Visualization, Abdominolpelvic Surgery.
What interventions are being tested in trial NCT05754333?
The interventions under investigation include: pudexacianinium chloride (DRUG).
Who is sponsoring clinical trial NCT05754333?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05754333 being conducted?
This trial has 6 study locations across Florida, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraoperative Ureter Visualization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05754333's enrollment target sits among peer trials
107 1666th of 2000 higher than 335 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI